A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Summary

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Heart Failure

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Boehringer Ingelheim

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites